Eosinophil LNK deficiency promotes EETs and thrombosis. (A) Eosinophil, neutrophil, monocyte, and platelet counts in WT, Lnk^f/f, and eoCreLnk^f/f mice. (B-C) P-stat5 (B) and CD69 (C) levels in eosinophils. (D) FeCl₃-induced carotid artery occlusion in WT, Lnk^f/f, and eoCreLnk^f/f mice. (E) Representative images and quantifications of EETs using MBP (green) with H3Cit (red) in thrombi of WT, Lnk^f/f and eoCreLnk^f/f mice. (F) Quantification of NETs using MPO with H3Cit (MPO+H3Cit+) per thrombi. (G) Representative images and quantification of EETs (H3Cit+, red) at basal and stimulated conditions in WT, Lnk^f/f, and eoCreLnk^f/f BM-derived eosinophils. (H) Representative images and quantification of NETs (Ly6G⁺H3Cit⁺/Ly6G⁺Dapi⁺) in neutrophils incubated with WT, Lnk^f/f or eoCreLnk^f/f BM derived eosinophils for 4 hours. (I) FeCl₃-induced carotid artery occlusion and quantification of NETs in eoCreLnk^f/f mice treated with and without 400 U DNase I. (J-K) Quantification of EETs (J) and NETs (K) per thrombi. Unpaired t test. (L) FeCl₃-induced carotid artery occlusion in Lnk^f/f and eoCreLnk^f/f mice with isotype control antibody or anti-Ly6G antibody. IV injection (250 μg per mice) 3 times per week. (M) Representative images and quantifications of EETs using MBP (green) with H3Cit (red) in thrombi of Lnk^f/f and eoCreLnk^f/f mice with isotype control or anti-Ly6G antibody. (N) Representative images and quantifications of NETs using MPO (green) with H3Cit (red) in thrombi of Lnk^f/f and eoCreLnk^f/f mice with isotype control or anti-Ly6G antibody. Data are expressed as mean (red bar) ± standard error of the mean (SEM). Scale bar, 100 μm.